Enhancement of liver parenchyma after injection of hepatocyte‐specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine
Open Access
- 23 January 2010
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 31 (2) , 356-364
Abstract
Purpose: To compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte‐specific contrast media.Materials and Methods: Patients (n = 295) with known/suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1‐weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs).Results: The relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed‐imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46–2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%).Conclusion: In the delayed, hepatocyte‐specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine. J. Magn. Reson. Imaging 2010; 31: 356–364.Keywords
This publication has 28 references indexed in Scilit:
- Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesionsEuropean Radiology, 2007
- Liver Tumor CharacterizationJournal of Computer Assisted Tomography, 2006
- Efficacy and Safety of MR Imaging with Liver-specific Contrast Agent: U.S. Multicenter Phase III StudyRadiology, 2005
- Contrast Agents for MR Imaging of the LiverRadiologic Clinics of North America, 2005
- Improved Detection of Focal Liver Lesions at MR Imaging: Multicenter Comparison of Gadoxetic Acid–enhanced MR Images with Intraoperative FindingsRadiology, 2004
- Contrast Agents for MR Imaging of the LiverRadiology, 2001
- Focal Liver Lesions: Evaluation of the Efficacy of Gadobenate Dimeglumine in MR Imaging—A Multicenter Phase III Clinical StudyRadiology, 2000
- Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosisJournal of Magnetic Resonance Imaging, 1998
- Pharmacokinetics of the Liver‐Specific Contrast Agent Gd‐EOB‐DTPA in Relation to Contrast‐Enhanced Liver Imaging in HumansThe Journal of Clinical Pharmacology, 1997
- Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.Radiology, 1995